Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nicotinic cholinergic modulation: galantamine as a prototype.

Diana S Woodruff-Pak1, Cynthia Lander, Hugo Geerts

  • 1Albert Einstein Healthcare Network, Korman Suite 100, 5501 Old York Road, Philadelphia, PA 19141, USA. woodrufd@einstein.edu.

CNS Drug Reviews
|December 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study.

Frontiers in pharmacology·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation Study.

CPT: pharmacometrics & systems pharmacology·2025
Same journal

Glial Cells in Aging and Neurodegeneration. A Satellite Symposium to the 28<sup>th</sup> Annual Meeting of the Society for Neuroscience. Los Angeles, CA, November 7, 1998.

CNS drug reviews·2017
Same journal

Neuron-Glial Interactions. The Sixth Annual University of Southern California Neuroscience Symposium, Los Angeles, November 6, 1998.

CNS drug reviews·2017
Same journal

The Pharmacology and Mechanism of Action of Zolpidem.

CNS drug reviews·2017
Same journal

Zonisamide: Pharmacology and Clinical Efficacy in Epilepsy.

CNS drug reviews·2017
Same journal

1998 Annual Meeting of the Society for Neuroscience: New Drugs Affecting the Central Nervous System. Los Angeles, California, November 7-12, 1998.

CNS drug reviews·2017
Same journal

Application of Gene Knockout Technique to Alcohol Research. Satellite Symposium to the 28<sup>th</sup> Annual Meeting of the Society for Neuroscience. Los Angeles, CA, November 7, 1998.

CNS drug reviews·2017
See all related articles

This review examines nicotinic acetylcholine receptors in Alzheimer's disease, highlighting galantamine's dual action. Galantamine enhances cognition by inhibiting acetylcholinesterase and modulating nicotinic receptors.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Nicotinic acetylcholine receptor (nAChR) pharmacology is crucial for understanding neurodegenerative diseases, particularly cognitive and behavioral symptoms.
  • Allosteric modulation of nAChRs is a key area for developing new therapeutic agents.
  • Changes in nAChRs are observed in Alzheimer's disease (AD).

Purpose of the Study:

  • To review the scientific evidence for alterations in nAChRs in Alzheimer's disease.
  • To examine the pharmacology of galantamine, a drug approved for cognitive enhancement in AD.
  • To assess preclinical evidence for galantamine's efficacy in learning and memory.

Main Methods:

  • Review of existing scientific literature on nAChRs in AD.
  • Analysis of galantamine's pharmacological profile, including its effects on acetylcholinesterase and nAChRs.

Related Experiment Videos

  • Evaluation of preclinical studies investigating galantamine's impact on learning and memory.

    • Main Results:

    • Galantamine exhibits a dual mechanism of action: modest inhibition of acetylcholinesterase and an allosteric potentiating ligand effect at nAChRs.
    • Preclinical studies suggest galantamine's efficacy in improving learning and memory.

    Conclusions:

    • The combined action of acetylcholinesterase inhibition and nAChR modulation by galantamine may offer significant therapeutic benefits in Alzheimer's disease.
    • This dual mechanism potentially facilitates acetylcholine neurotransmission more effectively than acetylcholinesterase inhibition alone.